chemo-immunotherapy in nsclc: the keynote-189 trial
Published 5 years ago • 144 plays • Length 4:53Download video MP4
Download video MP3
Similar videos
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:57
keynote 189: targeting nsclc patients with brain and liver metastases
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
5:00
administering the keynote-189 regimen in nondriver mnsclc
-
2:08
using first-line immunotherapy in stage 4 nsclc
-
4:15
nondriver mnsclc: optimizing the keynote-189 regimen
-
4:05
pembrolizumab chemotherapy in newly diagnosed nsclc
-
5:12
nondriver mnsclc: stratifying to the keynote-189 regimen
-
8:13
has the keynote-189 trial defined a clear standard of care? (bmic-022)
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
4:47
benefit of pembrolizumab in nsclc: the keynote trials
-
7:01
actual use of pembrolizumab and chemotherapy in nsclc
-
8:52
immunotherapy chemotherapy in nonsquamous nsclc